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Abstract
Background: The Salivaomics Knowledge Base (SKB) is designed to serve as a computational infrastructure that can 
permit global exploration and utilization of data and information relevant to salivaomics. SKB is created by aligning (1) 
the saliva biomarker discovery and validation resources at UCLA with (2) the ontology resources developed by the OBO 
(Open Biomedical Ontologies) Foundry, including a new Saliva Ontology (SALO).
Results: We define the Saliva Ontology (SALO; http://www.skb.ucla.edu/SALO/) as a consensus-based controlled 
vocabulary of terms and relations dedicated to the salivaomics domain and to saliva-related diagnostics following the 
principles of the OBO (Open Biomedical Ontologies) Foundry.
Conclusions: The Saliva Ontology is an ongoing exploratory initiative. The ontology will be used to facilitate 
salivaomics data retrieval and integration across multiple fields of research together with data analysis and data mining. 
The ontology will be tested through its ability to serve the annotation ('tagging') of a representative corpus of 
salivaomics research literature that is to be incorporated into the SKB.
Background
Saliva (oral fluid) is an emerging biofluid for non-invasive
diagnostics used in the detection of human diseases. The
need to advance saliva research is strongly emphasized by
the National Institute of Dental and Craniofacial
Research (NIDCR), and is included in the NIDCR's 2004-
2009 expert panel long-term research agenda [1]. The
ability to monitor health status, disease onset, progres-
sion, recurrence and treatment outcome through non-
invasive means is highly important to advancing health
care management. Saliva is a perfect medium to be
explored for personalized individual medicine including
diagnostics, offering a non-invasive, easy to obtain means
for detecting and monitoring diseases. Saliva testing
potentially allows the patient to collect their own saliva
samples at home, yielding convenience for the patient and
savings in health costs, and facilitating multiple sampling.
Specimen collection is less objectionable to patients and
easier in children and elderly individuals.
Due to these advantages, finding biomarkers in saliva
for the detection of serious illnesses such as cancers has
been on the national healthcare agenda for several years,
and the National Cancer Institute has accordingly recog-
nized saliva as a promising source for cancer biomarkers
[2]. A mandate in the Government Performance Report
Act (GPRA) report is that by year 2013 proof of principle
will be obtained for the ability of saliva to monitor health
and diagnose one systemic disease [3].
For the past six years the UCLA salivaomics research
group has developed proteome, transcriptome,
microRNA, metabolome, genome, microbiome, and
point-of-care salivary diagnostic technologies. These
research resources have proved highly valuable to basic
and translational research groups around the world.
Sjögren's syndrome (SS) is an autoimmune disease that
affects exocrine tissues, especially salivary glands and lac-
rimal glands. The autoimmune-mediated damage of the
salivary and lacrimal glands leads to a decrease in the
production of saliva and tears and to the development of
dry mouth and dry eyes. Without the lubricating and pro-
tective functions of saliva and tears, the oral and ocular
surfaces are subject to infections and discomfort leading
to significantly reduced quality of life. The disease can
present either as primary Sjögren's syndrome (pSS), when
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Page 2 of 8no other autoimmune diseases are present, or as second-
ary Sjögren's syndrome (sSS), which involves co-presence
of some other autoimmune diseases. Sjögren's syndrome
is one of the most common autoimmune disorders in the
US, with an estimated prevalence of ~4 million people,
affecting primarily women (in a ratio of 9 to 1). In addi-
tion, pSS patients have a 40-fold higher risk of developing
malignant lymphoma than the general population.
The rapid development and maturity of the genomics
field has led to the emergence of other omics studies,
such as proteomics and transcriptomics, which are now
being implemented widely in studies of human disease.
Clearly, mining the data from multiple omics studies can
provide deeper insight into the workings of biological sys-
tems than can be obtained from any single omics study.
Omics databases such as PharmGKB (the Pharmacog-
enomics Knowledge Base [4]) and EPO-KB (the Empiri-
cal Proteomic Ontology Knowledge Base [5]) serve as
important resources for the emerging discipline of sys-
tems biology as applied to the understanding of patho-
genesis in humans and in model organisms. However,
systematic management and analysis, and above all the
integration, of omics datasets remains challenging, and
the problems are compounded when these datasets need
to be integrated with data of other sorts, including diag-
nostic data obtained by clinicians.
As a computational and informatics infrastructure that
can permit global exploration and utilization, the Sal-
ivaomics Knowledge Base (SKB) is being created by align-
ing (1) the saliva biomarker discovery and validation
resources at UCLA with (2) the ontology resources devel-
oped by the OBO (Open Biomedical Ontologies)
Foundry [6], including the new Saliva Ontology (SALO)
that is described in this communication.
The Salivaomics Knowledge Base (SKB; http://
www.skb.ucla.edu/) is a data repository, management sys-
tem and web resource constructed to support human sali-
vary proteomics, transcriptomics, miRNA, metabolomics
and microbiome research. The SKB will provide the first
web resource dedicated to salivary omics studies and will
contain the data and information needed to explore the
biology, diagnostic potentials, pharmacoproteomics and
pharmacogenomics of human saliva. At the same time it
will allow a systems approach to the utilization of salivary
diagnostic technology for personalized medicine applica-
tions. It has an effective information retrieval system and
carefully designed data format and employs an open data
model. Figure 1 shows the SKB's three-tier service ori-
ented architecture with a Data Layer, Ontology Layer and
Interface Layer.
Results and Discussion
We are creating the Saliva Ontology (SALO; http://
www.skb.ucla.edu/SALO/) as a consensus-based con-
trolled vocabulary of terms and relations dedicated to sal-
ivaomics and to saliva-related diagnostics. Figure 2
displays a fragment of SALO in its current form.
SALO
The Saliva Ontology (SALO) is being created through
cross-disciplinary interaction between saliva experts,
protein experts, diagnosticians, and ontologists. To aid
development and testing of SALO, we are incrementally
developing a corpus of saliva-relevant literature in SKB to
assist in identifying core terms, synonyms and definitions
for inclusion within the ontology, and to provide exam-
ples of usage and links between SALO content and the
corresponding items through their PubMed identifiers.
In this way a growing body of semantically enhanced
web-enabled literature will be created within the SKB to
support future research. Additional resources upon
which we will draw in populating and validating SALO
will include the results of experiments in data- and text-
mining using the ontology, and cross-linking to existing
ontologies and terminology resources involving treat-
ment of saliva-relevant phenomena. We will also identify
and represent within SALO relationships to saliva-rele-
vant types represented in ontologies such as Gene Ontol-
ogy (GO) [7], the Protein Ontology (PRO) [8], Ontology
for Biomedical Investigations (OBI) and Chemical Enti-
ties of Biological Interest (CHEBI) [9] and also provide
links to corresponding SNOMED CT terms where avail-
Figure 1 The SKB architecture. The SKB is based on a three-layer ar-
chitecture. Data sources are stored in the data layer. In the ontology 
layer data elements from these data sources are mapped to nodes in 
controlled vocabularies. The interface layer allows query, browsing and 
submission. For instance, the interface layer receives user requests, 
submits queries to the data layer through the ontology layer and ob-
tains corresponding results. The three layers connect data from con-
sumers (users submitting query) with data providers (data sources) via 
ontologies.
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Page 3 of 8able. To facilitate the maintenance of SALO and its use in
literature curation, text-mining tools such as GATE http:/
/gate.ac.uk/ and the Python Natural Language Toolkit are
being used.
SALO will be a public domain resource and entirely
web-based. Each term in the ontology will have its own
URL which will point to a webpage providing definitions,
PubMed sources, references to annotations in SKB and to
external databases. The goal of the SKB is then to inte-
grate, store, organize and manage all saliva-relevant
experimental data annotated and connected through
SALO and its associated ontologies. SKB will include also
data about saliva-related experiments, which will be cap-
tured using the Ontology for Biomedical Investigations
(OBI) in tandem with the SALO ontology.
SALO Development
In order to build on the solid foundations of prior work
on biomedical ontologies and on the associated software
tools and ontology application techniques, we will work
with the Open Biomedical Ontologies (OBO) Foundry,
and with the developers of OBO ontologies such as GO,
PRO, CHEBI, and OBI in order to ensure conformity with
current best practices and to guarantee non-redundant
development. We follow the principles of the OBO
Foundry in constructing SALO in order to ensure that
SALO is semantically interoperable with the other OBO
ontologies[6].
Salivaomics Standard Literature Corpus
We have access to full-text articles of the biomedical jour-
nals from PubMed until 2009 and are using these as our
primary resource in creating the Salivaomics Standard
Literature Corpus (draft version here: http://
www.skb.ucla.edu/SSLC/). First we created a list of repre-
sentative saliva literature items in collaboration with the
following scientific leaders (in alphabetical order by last
name) in saliva research:
- Arie V. Nieuw Amerongen (Free University and Uni-
versity of Amsterdam, The Netherlands)
- Bruce Baum (National Institutes of Health/NIDCR)
- William Giannobile (University of Michigan)
- James Melvin (University of Rochester)
- Nelson Rhodus (University of Minnesota)
- Charles Streckfus (The University of Texas Health
Science Center at Houston)
- Arjan Vissink (University Medical Center Gronin-
gen, The Netherlands)
- Stephen Wotman (Case Western Reserve Univer-
sity)
- Chih-Ko Yeh (University of Texas Health Science
Center at San Antonio).
31 literature items for inclusion were then selected on
the basis of numbers of citations. Some of the articles in
the corpus are specifically related to the Sjögren's syn-
drome test-case. This corpus now forms a constituent
part of the SKB, where the SALO ontology, in tandem
with GO, PRO and other ontologies, is being applied to
create semantically enhanced versions of the initially
selected representative articles through a process of man-
ual curation.
In an interesting positive feedback effect, the process of
annotating the corpus will in addition bring benefits to
the process of development of the SALO ontology itself,
Figure 2 A fragment of SALO in its current form.
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covered in the process of curation. Where an expression
that is relevant to saliva research is used in the corpus but
is not already present in SALO, a new ontology term will
be proposed and then either added to SALO or submitted
to one of the other relevant ontologies for inclusion. In
this way, the comprehensiveness of SALO can be incre-
mentally achieved relative to the state of the art in sal-
ivaomics research at any given stage, and in a way which
ensures the alignment of SALO with other major ontolo-
gies.
In addition to the manual curation of the saliva corpus,
we are also using text-mining algorithms to the 23,467
PubMed articles identified as containing occurrences of
the term "saliva" in their title or abstract. Specifically we
are applying information extraction algorithms for seg-
mentation, part-of-speech tagging, semantic labelling,
and entity and relation chunking recognition to these
articles. Figure 3 displays the result of entity chunking
recognition applied to the text of one sample article.
This strategy, too, will identify additional terms needed
in the Saliva Ontology or in the related ontologies with
which SALO must interoperate. We will thus pursue both
manual and automatic processes for annotating the litera-
ture in our corpus, amending SALO incrementally, and
also submitting necessary amendment requests to related
ontologies as we proceed.
SALO Resources
The Saliva Ontology consists of both hierarchical (is_a)
structures supporting saliva-domain taxonomies and
additional relationships (such as part_of, derives_from,
has_function) taken from the OBO Relation Ontology
[10]. Figure 4 illustrates some illustrative examples of
links between SALO and other ontologies.
SALO is a formal ontology created using the W3C stan-
dard Ontology Web Language (OWL 2.0). The public
release OWL versions of the ontology will be published in
the NCBO BioPortal. For quality assurance and dissemi-
nation purposes, parallel versions will be created (using
standard conversion software) in the OBO format that is
used by the GO Consortium and still favored by many
biologists. These OBO versions will be submitted for
inclusion in the OBO ontology library.
SALO will employ the OBO Foundry principles http://
www.obofoundry.org/crit.shtml in its development. This
will help to ensure that the ontology is open, well-docu-
mented, specific to the domain (saliva, including sal-
ivaomics), and that it works well with other biomedical
ontologies. The principles require that both logical and
natural language definitions are provided for each term in
the ontology, and also that links between terms are
asserted using relational expressions which have been
logically defined in a way to the OBO Relation Ontology
[10]. Cross-ontology reasoning is thereby supported by
the definitional structure of the ontologies involved.
Ontology of the Salivary Markers for Sjögren's Syndrome 
(SS)
SALO will be tested specifically in light of its capacity to
meet the ontology needs for managing data derived from
research on the use of a salivary genetic marker for
Sjögren's syndrome (SS).
In results of a complete screening for the TRIM21 gene
in patients with primary SS are presented [11], together
with results of a gene association study. A single-nucle-
Figure 3 A result of entity chunking recognition for the text of 
one sample article.
Figure 4 Links between SALO and other ontologies.
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strongly associated with the presence of anti-Ro 52 kd
autoantibodies in primary SS.
SS-relevant portions of our ontology will be validated
through our work on annotation of representative
research literature on Sjögren's syndrome (including
Sjögren's Syndrome Knowledge Base http://
sskb.umn.edu/), through our research on the SS-A pro-
tein and on the TRIM21 gene. Figure 5, illustrates some
of the relations involved in a saliva-specific genetic
marker for Sjögren's syndrome.
The end-result of this work is two-fold: (1) A better
understanding of relationships between diseases and
multiple biomarkers because more useful information
can be obtained based on the ontology annotation and
classification. (2) A better aid for data interpretation,
analysis and mining through the ontology annotation.
Conclusions
Saliva Ontology is an ongoing exploratory initiative. The
ontology is being constructed to interoperate with the
Gene Ontology (GO), the Protein Ontology (PRO), the
CHEBI Small Molecule Ontology and other standard
ontology and terminology resources, including SNOMED
CT. The ontology will be used to facilitate salivaomics
data retrieval and integration across multiple fields of
research together with data analysis and data mining. The
ontology will be tested through its ability to serve the
semantic enhancement of a representative corpus of sal-
ivaomics research literature that is to be included in the
SKB.
Methods
Ontology is the science of what is, of the kinds and struc-
tures of objects, properties, events, processes and rela-
tions in every area of reality [12]. As applied in the
biomedical domain, ontology plays a key role in providing
consensus-based controlled vocabularies serving the con-
sistent annotation of biological and medical data and
information, most conspicuously within the framework
of the Gene Ontology (GO) [7] and now of its sister
ontologies within the Open Biomedical Ontologies
Foundry http://obofoundry.org. We believe that an
approach to the analysis of saliva in terms of a controlled
structured vocabulary and a common set of measure-
ment data elements developed along OBO Foundry lines
can provide a cost-effective approach to support the
coordinated screening of large populations in such a way
as to yield data that is capable of being aggregated for sta-
tistical purposes and for example in the context of meta-
analysis.
Currently, ontologies support data integration primar-
ily through data annotation (or 'tagging'), including the
annotation of data reported in the peer-reviewed scien-
tific literature [13]. While the value of such data annota-
tion has been demonstrated in molecular and model
organism biology and in the analysis of gene expression
data [14-16], the potential of ontology-based annotation
in the clinical domain has been largely unrealized due to
limitations in current ontology development practices,
including:
1. Most ontologies consist of only a few well-defined
relations, primarily the is_a (e.g. heart is_a organ) and
part_of (e.g. aortic valve part_of heart) relations, and
they only relate terms within a single taxonomy
[17,18]. This results in an inability to capture higher
levels of biological complexity.
2. Most ontologies and terminology artifacts lack a
sound logical underpinning, rest on mixed modes of
classification and inadequate formal definitions,
resulting in an inability to support sophisticated com-
putation [19-24].
To address these and related shortfalls, the OBO
Foundry was created in 2006 by a group of developers of
OBO ontologies on the basis of an evolving set of princi-
ples designed to foster the creation of an evolving set of
best practice in ontology development. The first list of
ontologies satisfying OBO Foundry peer review was
released in April 2010. OBO ontologies are designed to
represent in an interoperable fashion the biomedical real-
ity from which data are sampled. Their development
within the framework of a common top-level ontology
(Basic Formal Ontology [25]) and consistent employment
of a common set of relations [10] allows Foundry ontolo-
gies to be used together as interoperable modules within
an evolving larger network. The relations themselves are
Figure 5 Relations involved in a saliva-specific genetic marker for 
Sjögren's syndrome.
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ticated computation both within and across ontologies
[10].
We capitalize on and contribute to the OBO Foundry
initiative in this work. One important element therein is
the distinction between reference and application ontolo-
gies. [26]. The former correspond in medicine to the basic
biomedical sciences such as anatomy and physiology. The
latter correspond to the clinical specialisms and sub-spe-
cialisms, for example pediatric surgery or radiation
oncology. Just as the clinical specialisms draw on the
methods, theories and terminologies of the basic biomed-
ical sciences for a variety of purposes, including the edu-
cation of clinicians and the formulation of clinical
research hypotheses, so, within the OBO Foundry frame-
work, application ontologies draw on reference ontolo-
gies to serve as feeders of lexically more simple terms
(such as 'protein' or 'disease') to be used in the construc-
tion of the more specialized compound terms by which
the application ontologies are composed.
SALO is in this sense an application ontology. It draws
primarily on four reference ontologies - Protein Ontology
(PRO), Gene Ontology (GO), Chemical Entities of Bio-
logical Interest (CHEBI) and Ontology for Biomedical
Investigations (OBI) - which are described in more detail
below. All terms in SALO, other than those created anew
because they relate specifically to the SALO domain, will
as far as possible be derived from the mentioned sources.
Thus for example all protein terms in SALO will be taken
from the Protein Ontology. Where PRO does not have
the needed terms, then requests for inclusion of these
terms in PRO will be submitted to the PRO tracker [8].
The Protein Ontology (PRO)
The Protein Ontology Consortium, led by researchers
affiliated with the Universal Protein Knowledgebase
(UniProt, http://www.pir.uniprot.org/), developed the
PRO framework [8] with two axes of classification, based,
respectively, on the protein structural units of domains,
and on full-length protein sequences and their modifica-
tions. This second axis represents the various protein
entities (such as splice variants, cleavage products) that
can derive from a single gene.
Because proteins themselves are combinations of
domains with additional sequence, the two axes of classi-
fication are related via the has_part relation. We are col-
laborating with PRO's developers in the curation of those
sections of PRO relating to those proteins which are of
primary interest to the saliva domain. We will also partic-
ipate in PRO dissemination activities in order to expand
the community of users of both SALO and SKB.
The Gene Ontology (GO)
The Gene Ontology (GO) project is a collaborative effort
to develop and use ontologies to support biologically
meaningful annotation of genes and their products in a
wide variety of organisms. Major model organism data-
bases and other bioinformatics resource centers contrib-
ute to the project [27]. The GO provides a systematic
language for the consistent description of attributes of
genes and gene products in three key biological domains
that are shared by all organisms: molecular function, bio-
logical process and cellular component. GO's value
derives in large part from the fact that it has been utilized
for the systematic annotation by trained biologist-cura-
tors of experimental results pertaining to multiple species
of organisms and communicated in the peer-reviewed
scientific literature. Some 50,000 journal articles have
been annotated in this way, and their content has thereby
been made accessible to computer-aided discovery. We
will collaborate with GO's developers in the curation of
those sections of GO relating to gene products of primary
interest to the saliva domain.
Chemical Entities of Biological Interest (CHEBI)
Chemical Entities of Biological Interest (CHEBI) is a
freely available ontology of molecular entities focused on
'small' chemical compounds. The molecular entities in
question are either natural products or synthetic prod-
ucts used to intervene in the processes of living organ-
isms. Genome-encoded macromolecules (nucleic acids,
proteins and peptides derived from proteins by cleavage)
are not as a rule included. In addition to molecular enti-
ties, CHEBI contains what are called 'groups' (parts of
molecular entities) and classes of entities. CHEBI
includes an ontological classification whereby the rela-
tionships between molecular entities or classes of entities
and there is_a parents and children are specified. CHEBI
is available online at http://www.ebi.ac.uk/chebi/[9]. We
will collaborate with CHEBI's developers in the curation
of those sections of CHEBI relating to the chemical com-
pounds of primary interest in the saliva domain.
Ontology for Biomedical Investigations (OBI)
The Ontology for Biomedical Investigations (OBI)
addresses the need for controlled vocabularies to support
integration of experimental data, a need originally identi-
fied in the transcriptomics domain by the Microarray
Gene Expression Data Society (MGED), which developed
the MGED Ontology as an annotation resource for
microarray data. In response to the recognition of con-
vergent needs in areas such as protein and metabolite
characterization, this effort was broadened to become
what was initially known as FuGO (Functional Genomics
Investigation Ontology) - the ontology associated with
the FUGE (Functional Genomics Experiment) data model
[28]. The coverage of FuGO was then further expanded in
2006 to include clinical trials and epidemiological studies,
biomedical imaging and a variety of further experimenta-
tion domains, to become what is today OBI, an ontology
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designs, protocols, instrumentation, materials, processes,
data and types of analysis in all areas of biological and
biomedical investigation. Twenty five groups are now
involved in building OBI, deriving from all areas of omics
research, and the Foundry discipline, including the BFO
(Basic Formal Ontology) top-level framework, has proven
essential to its distributed development [6]. OBI is used
in our work as a source for ontological representation of
biomarkers and related terms pertaining to sample col-
lection and to diagnostic and experimental uses of saliva,
as well as to associated protocols, instrumentation, statis-
tical methods, and so forth.
SNOMED CT
Since SALO is designed for use in support of clinical
research and treatment, it is important that it be aligned
as closely as possible with the SNOMED® Systematized
Nomenclature of Medicine, which is designed to provide
the terminology needed to code the entire medical
record. The current version of SNOMED is SNOMED
CT (for 'Clinical Terms'), which is maintained by the
International Health Terminology Standards Develop-
ment Organization (IHTSDO) in Copenhagen. At its sim-
plest, SNOMED CT is a controlled vocabulary of
expressions used in healthcare reporting, as for example
in an electronic health record. 'Controlled' means that the
content of the terminology is designed to provide a well-
managed non-redundant set of codes and associated
expressions to ensure consistency of clinical coding.
Quality assurance procedures are in place, which are
designed to ensure that the terminology is structurally
sound, biomedically accurate and consistent with current
practice.
Unfortunately, while SNOMED is built around an
evolving core vocabulary that is largely the work of the
College of American Pathologists (CAP), it has been sub-
jected at different times to various different sorts of com-
binations with other terminological resources, deriving
mainly from the UK. The result is that, even after consid-
erable efforts on the part of the new IHTSDO organiza-
tion, SNOMED remains a terminology resource that is
marked by multiple redundancies and associated incon-
sistencies of coding [29]. It is for this reason that we did
not utilize SNOMED content in constructing SALO, but
rather are working to ensure alignment between
SNOMED CT and the results of our work on the Saliva
Ontology by incorporating SNOMED CT terms where
needed. At the same time, we will submit all clinically rel-
evant new saliva-related terminology content created
within the SALO framework to the IHTSDO Content
Committee with a recommendation for inclusion for
inclusion in future versions of SNOMED CT.
Saliva and Ontology
No dedicated ontology has thus far been defined in direct
relation to oral biological fluids [30], and the treatment of
saliva in ontology and terminology resources has thus
been insufficient for purposes of saliva research.
SNOMED CT returns 39 records for the search term
'saliva', including 'saliva (substance)', 'normal saliva (find-
ing), and 'saliva-induced contact dermatitis (disorder)'.
Saliva (substance) is asserted in the SNOMED CT con-
cept hierarchy to be a digestive system fluid, which is in
turn a body fluid. In The Foundational Model of Anatomy
ontology (FMA), saliva is a subordinate of portion of
secreted substance; no definition is provided [17]. Given
the intention of the IHTSDO to align the SNOMED
treatment of anatomy (including bodily substances) with
that of the FMA, and given our existing collaboration
with both the IHTSDO editorial community and the
FMA's developers, we will work with both communities
to create, through SALO, a more detailed representation
of the ontology of this bodily fluid that is optimized to
meet the needs of both the clinical diagnostic community
and the cross-disciplinary community of omics research-
ers.
Results similar to those obtained from the analysis of
SNOMED apply also to other terminology resources. The
Cyc ontology (which contains hundreds of thousands of
terms in all domains) [31], defines Saliva is: A Type of:
bodily secretion and liquid, whereby it is asserted merely
that it is: An Instance of tangible stuff type.
In WordNet, saliva is defined as a clear liquid secreted
into the mouth by the salivary glands and mucous glands
of the mouth; it is asserted that saliva moistens the mouth
and starts the digestion of starches [32].
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